Search

Zentalis Pharmaceuticals Inc

Lezárt

3.08 0.33

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

2.98

Maximum

3.17

Fő mutatók

By Trading Economics

Bevétel

-42M

-78M

Egy részvényre jutó nyereség

-0.59

Munkavállalók

106

EBITDA

-42M

-77M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+185.71% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 6.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

335K

331M

Előző nyitás

2.75

Előző zárás

3.08

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 17. 23:56 UTC

Targa Resources Corp is trading modestly higher in after-market hours, recovering from an early decline and reaching a high near the session's end.

2026. szept. 17. 23:56 UTC

Correlated Moves

Synaptics Inc declined during after-market hours, moving lower alongside the Nasdaq 100 Index amid positive economic data, including a drop in jobless claims.

2026. szept. 17. 23:56 UTC

TransUnion is trading modestly higher in after-market hours, despite earlier gains settling and the price remaining below its 20-day moving average.

2026. szept. 17. 23:56 UTC

Event
News

Rexford Industrial Realty completed a $1.2 billion sale of a 22-property portfolio to EQT Real Estate, with shares slightly declining in after-market trading.

2026. szept. 17. 23:56 UTC

Correlated Moves

Saia Inc's shares traded roughly flat during after-market hours, remaining below the 20-day moving average and near the lower end of its one-month range.

2026. szept. 17. 23:56 UTC

Fidelity National Information Services Inc is trading modestly higher in after-market hours following four consecutive sessions of losses, amid positive economic indicators.

2026. szept. 17. 23:52 UTC

Pinterest Inc is trading higher in after-market hours, continuing a trend of higher daily closes since Thursday's close, despite recent divergence from upward momentum.

2026. szept. 17. 23:51 UTC

Organon & Co. is experiencing a modest decline in after-market trading, remaining below its 20-day moving average and near the lower end of its one-month trading range.

2026. szept. 17. 23:51 UTC

Hawkins Inc is advancing in after-market trading, reaching its highest cumulative return of the day amid a one-month trading range.

2026. szept. 17. 23:51 UTC

Turning Point Brands Inc has advanced in after-market trading, recovering sharply from a low immediately following Thursday's close, contributing to an overall higher position.

2026. szept. 17. 23:51 UTC

TransDigm Group Inc is seeing modest gains in after-market trading, recovering from earlier lows but remains below its 20-day moving average.

2026. szept. 17. 23:51 UTC

American Electric Power Company Inc is trading modestly lower in after-market hours, continuing a decline from Thursday's close and remaining below its 20-day moving average.

2026. szept. 17. 23:51 UTC

Alliant Energy Corp is trading modestly higher in after-market hours, showing stability with slight upward movement and fluctuations within a narrow range.

2026. szept. 17. 23:51 UTC

Correlated Moves

BHP Group Ltd is advancing in after-market trading, reflecting a notable upward movement since Thursday's close, despite remaining below its 20-day moving average.

2026. szept. 17. 23:51 UTC

CRISPR Therapeutics AG declined modestly during after-market hours on Thursday, breaking a recent trend of higher daily closes.

2026. szept. 17. 23:51 UTC

Chicago Fed National Activity Index Release on September 21, 2026: Market Awaits Insights Amid Cautious Optimism and Inflation Concerns.

2026. szept. 17. 23:51 UTC

Mortgage Rates Hit 6.97%, Highest Since May 2025, as Market Sentiment Wanes Ahead of Upcoming MBA Release

2026. szept. 17. 23:51 UTC

Japan's Core Inflation Rate for August at 1.7% Falls Short of Expectations, Raising Concerns Over Economic Stability and Monetary Policy Effectiveness

2026. szept. 17. 23:51 UTC

Japan's August Inflation Rate at 1.9% Falls Short of Expectations, Raising Concerns for Monetary Policy Adjustments Amidst Weak Demand

2026. szept. 17. 23:51 UTC

Correlated Moves

Las Vegas Sands Corp is trading modestly higher in after-market hours, following a pullback earlier in the session, aligning with Wynn Resorts Ltd's gains.

2026. szept. 17. 23:51 UTC

Regeneron Pharmaceuticals Inc is trading modestly lower in after-market hours, remaining significantly below its 20-day moving average after a volatile session.

2026. szept. 17. 23:51 UTC

FedEx Corp is trading modestly lower in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month trading range.

2026. szept. 17. 23:51 UTC

ICU Medical Inc declined in after-market trading, reaching its lowest point shortly after the market closed and remaining below its 20-day moving average.

2026. szept. 17. 23:51 UTC

In after-market trading, Dave and Buster's Entertainment, Inc. is advancing, reflecting a notable increase since Thursday's close, despite being below its 20-day moving average.

2026. szept. 17. 23:51 UTC

SLB NV is trading modestly higher in after-market hours, following fluctuations that led to a cumulative return of 0.89% shortly after the market closed.

2026. szept. 17. 23:51 UTC

Correlated Moves

Cardinal Health Inc is trading modestly higher in after-market hours, following a slight uptick in Cencora Inc, which is recovering from recent declines.

2026. szept. 17. 23:51 UTC

Bath & Body Works Inc. is declining in after-market trading, currently near its lowest point of the day and below its 20-day moving average.

2026. szept. 17. 23:46 UTC

Ecolab Inc is trading modestly higher in after-market hours, though it remains below its 20-day moving average and near the lower end of its one-month range.

2026. szept. 17. 23:46 UTC

Daqo New Energy Corp is trading higher in after-market hours, closing at its highest point despite challenges, as U.S. jobless claims fell to 196k.

2026. szept. 17. 23:46 UTC

N-Able Inc gained in after-market trading, advancing since Thursday's close and stabilizing above its 20-day moving average near the upper end of its one-month range.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

185.71% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 8.8 USD  185.71%

Magas 11 USD

Alacsony 5 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

5

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.